Following the announcement of "scraping bones to cure poison", the management of Bloomage Biotech (688363) has changed significantly. On March 19, Bloomage Biotech announced that the company will hold a board meeting on March 18, 2025 to review and approve the adjustment and appointment of senior management.

The announcement mentioned that Liu Aihua will no longer hold the position of deputy general manager and will no longer hold any position in the company because he has exceeded the statutory retirement age.

The other two deputy general managers have also changed: Xu Guixin and Luan Yizheng are no longer deputy general managers and no longer belong to the senior management sequence, but they will continue to work in the company as vice presidents of business. The announcement mentioned that Liu Aihua held 70,800 shares of the company, Xu Guixin held 44,200 shares, and Mr. Luan Yizheng held 55,200 shares.

At the same time, the company hired Wang Hui and Xiang Maogong as deputy general managers, Wang Hui is currently the company's chief financial officer, and Xiang Maogong is the executive director of the global supply chain platform.

Previously, on the evening of March 3, Zhao Yan, director of Bloomage Biotech, made a public speech at the president's office meeting, clearly proposing internal problems of "anti-corruption" and "tightening outsourcing". Zhao Yan bluntly said that due to the previous lax management, the company has bred many ills, "this year the company has begun to scrape the bones to cure the poison, we will not tolerate the historical problems of indulgence, all corrupt personnel regardless of their positions, must be within March 31 to explain the problem, submit resignation." ”

Now the problem of "lax management" is emerging.

Behind this move, Bloomage Biotech's performance has continued to decline in recent years. According to the 2024 performance report, Bloomage Biotech's total operating income was 5.38 billion yuan, a year-on-year decrease of 11.6%; The net profit attributable to the parent company was 160 million yuan, a sharp decrease of 72.3% year-on-year.